BioCentury
ARTICLE | Company News

Eddingpharm gains Chinese rights to Amarin's Vascepa

February 28, 2015 2:37 AM UTC

Amarin Corp. plc (NASDAQ:AMRN) granted Eddingpharm Inc. (Shanghai, China) exclusive rights to hypertriglyceridemia drug Vascepa icosapent ethyl in Greater China.

Amarin will receive $15 million up front and is eligible for $154 million in regulatory and sales milestones, plus tiered double-digit royalties. Eddingpharm will develop and commercialize Vascepa in mainland China, Hong Kong, Macao and Taiwan. Amarin will supply the drug. ...